You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR MUPIROCIN

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for MUPIROCIN

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00108160 ↗	Preventing Staphylococcal (Staph) Infection	Completed	Saint Joseph Mercy Health System	Phase 4	2005-04-01	The purpose of this study is to determine if mupirocin 2% in polyethylene glycol (PEG) ointment [Treatment Arm] is effective in preventing moderate to severe re-infection with Staphylococcus aureus compared with treatment with polyethylene glycol (PEG) ointment [Placebo Arm].
NCT00108160 ↗	Preventing Staphylococcal (Staph) Infection	Completed	University of Michigan	Phase 4	2005-04-01	The purpose of this study is to determine if mupirocin 2% in polyethylene glycol (PEG) ointment [Treatment Arm] is effective in preventing moderate to severe re-infection with Staphylococcus aureus compared with treatment with polyethylene glycol (PEG) ointment [Placebo Arm].
NCT00108160 ↗	Preventing Staphylococcal (Staph) Infection	Completed	US Department of Veterans Affairs	Phase 4	2005-04-01	The purpose of this study is to determine if mupirocin 2% in polyethylene glycol (PEG) ointment [Treatment Arm] is effective in preventing moderate to severe re-infection with Staphylococcus aureus compared with treatment with polyethylene glycol (PEG) ointment [Placebo Arm].
NCT00108160 ↗	Preventing Staphylococcal (Staph) Infection	Completed	VA Office of Research and Development	Phase 4	2005-04-01	The purpose of this study is to determine if mupirocin 2% in polyethylene glycol (PEG) ointment [Treatment Arm] is effective in preventing moderate to severe re-infection with Staphylococcus aureus compared with treatment with polyethylene glycol (PEG) ointment [Placebo Arm].
NCT00156377 ↗	Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections	Completed	GlaxoSmithKline	Phase 4	2002-11-01	In order to evaluate the effect of eliminating nasal carriage by mupirocin prophylaxis on subsequent Staphylococcus aureus infection, a prospective randomized trial was performed particularly including patients with predisposing risk factors for S. aureus infections.
NCT00156377 ↗	Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections	Completed	University Hospital Muenster	Phase 4	2002-11-01	In order to evaluate the effect of eliminating nasal carriage by mupirocin prophylaxis on subsequent Staphylococcus aureus infection, a prospective randomized trial was performed particularly including patients with predisposing risk factors for S. aureus infections.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for MUPIROCIN

Condition Name

Chart
Table

Condition Name for MUPIROCIN
Intervention	Trials
Staphylococcus Aureus	9
Surgical Site Infection	6
Methicillin-resistant Staphylococcus Aureus	6
Impetigo	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for MUPIROCIN
Intervention	Trials
Infections	27
Staphylococcal Infections	26
Infection	24
Communicable Diseases	20
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for MUPIROCIN

Trials by Country

Map
Table

Trials by Country for MUPIROCIN
Location	Trials
United States	140
Spain	8
Ukraine	8
South Africa	6
Argentina	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for MUPIROCIN
Location	Trials
Missouri	11
Texas	9
Florida	8
New York	8
California	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for MUPIROCIN

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for MUPIROCIN
Clinical Trial Phase	Trials
Phase 4	31
Phase 3	11
Phase 2/Phase 3	3
[disabled in preview]	12
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for MUPIROCIN
Clinical Trial Phase	Trials
Completed	49
Recruiting	10
Unknown status	8
[disabled in preview]	13
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for MUPIROCIN

Sponsor Name

Chart
Table

Sponsor Name for MUPIROCIN
Sponsor	Trials
GlaxoSmithKline	7
Washington University School of Medicine	5
Agency for Healthcare Research and Quality (AHRQ)	5
[disabled in preview]	12
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for MUPIROCIN
Sponsor	Trials
Other	134
Industry	23
U.S. Fed	15
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.